NCT04811118 is a Phase 1 clinical trial of Docetaxel for Injection (Albumin-bound) in Advanced Solid Tumors, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Who is sponsoring NCT04811118?

NCT04811118 is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

What drugs are being tested in NCT04811118?

Interventions in NCT04811118: Docetaxel for Injection (Albumin-bound), Taxotere.

What condition does NCT04811118 study?

NCT04811118 studies Advanced Solid Tumors.

Is NCT04811118 still recruiting?

NCT04811118 is currently status unknown. Last updated 31 January 2022.

Last reviewed 2022-01-31 · How we verify

NCT04811118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Status unknown Phase 1 Last updated 31 January 2022

What this trial tests

Phase 1 trial testing Docetaxel for Injection (Albumin-bound) in Advanced Solid Tumors in 27 participants. Status unknown.

Timeline

18 May 2021

Primary endpoint
31 October 2022

31 December 2022

Quick facts

Lead sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	27
Start date	18 May 2021
Primary completion	31 October 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Docetaxel for Injection (Albumin-bound)
Taxotere (Docetaxel) — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, open-label, two-period, crossover trial to evaluate the pharmacokinetic profiles of albumin-bound docetaxel for intravenous infusion and Taxotere in patients with advanced solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Docetaxel for Injection (Albumin-bound)

Trials testing the same drug.

NCT06947291 — Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri · Phase 2 · recruiting

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04811118 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last refreshed: 31 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing